Search ↗

Comparison

Decapeptide-12 vs GHK-Cu

Decapeptide-12 is cosmetic & topical; GHK-Cu is healing & repair. They are compared here because they are frequently considered against each other, not because they act alike.

Decapeptide-12 GHK-Cu
Class Cosmetic & topical Healing & repair
Evidence Clinical trials Clinical trials
Human trials ~5 ~15
Half-life Topical ~30 minutes (systemic)
Reported range 1 mg 1-2 mg
Frequency Applied topically 2x daily at approximately 0.01-0.1% Daily topical, or subcutaneous in research protocols
Routes Topical Topical, Subcutaneous
FDA approved No No
Research use only No No
Banned in sport No No
Studied for Melasma, Hyperpigmentation, Skin brightening Skin repair and anti-ageing, Wound healing, Hair follicle stimulation
Reported side effects Mild irritation, Transient dryness Local irritation, Transient redness, Injection-site reactions

Decapeptide-12

Decapeptide-12 competitively inhibits tyrosinase, the rate-limiting enzyme converting tyrosine to melanin. Unlike hydroquinone, which is cytotoxic to melanocytes, it suppresses pigment production without destroying the cells, so it does not carry the ochronosis risk associated with prolonged hydroquinone use. Onset is correspondingly slower, typically requiring eight to sixteen weeks for visible change.

GHK-Cu

GHK is a tripeptide present in human plasma that declines markedly with age, and it binds copper(II) with high affinity to form GHK-Cu. The complex modulates expression of a large set of genes involved in tissue remodelling, stimulating collagen, elastin and glycosaminoglycan synthesis while influencing antioxidant and anti-inflammatory pathways. Its dermatological evidence is comparatively strong and includes controlled human trials; the systemic injectable use is far less supported.

Decapeptide-12 vs GHK-Cu: common questions

What is the difference between Decapeptide-12 and GHK-Cu?

Decapeptide-12 is cosmetic & topical and GHK-Cu is healing & repair, so they act on different pathways. Decapeptide-12: A tyrosinase-inhibiting peptide used for hyperpigmentation, positioned as a gentler alternative to hydroquinone. GHK-Cu: A naturally occurring copper-binding tripeptide with the strongest human evidence base of any compound in the healing group, mostly topical.

Which has stronger evidence, Decapeptide-12 or GHK-Cu?

They sit at the same evidence level: clinical trials. Decapeptide-12 has about 5 human studies and GHK-Cu about 15.

Are Decapeptide-12 and GHK-Cu FDA approved?

Neither is FDA approved for any indication.

References

Regulatory and primary sources

  1. PubChem compound record (CID 25087629) ↗ · structure, identifiers, synonyms
  2. PubChem compound record (CID 139035031) ↗ · structure, identifiers, synonyms
  3. CAS Registry Number 89030-95-5 ↗ · chemical identity

Published literature

  1. Hantash BM, Jimenez F. A split-face, double-blind, randomized and placebo-controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma.J Drugs Dermatol 2009.PubMed 19663110
  2. Kassim AT, Hussain M, Goldberg DJ. Open-label evaluation of the skin-brightening efficacy of a skin-brightening system using decapeptide-12.J Cosmet Laser Ther 2012.PubMed 22401652 · doi:10.3109/14764172.2012.672745
  3. Ramírez SP, Carvajal AC, Salazar JC, et al.. Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma.J Drugs Dermatol 2013.PubMed 23839199
  4. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.Int J Mol Sci 2018.PubMed 29986520 · doi:10.3390/ijms19071987
  5. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.Biomed Res Int 2015.PubMed 26236730 · doi:10.1155/2015/648108
  6. Mayfield CK, Bolia IK, Feingold CL, et al.. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.Am J Sports Med 2026.PubMed 41476424 · doi:10.1177/03635465251357593
  7. Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.J Am Acad Orthop Surg Glob Res Rev 2026.PubMed 41490200 · doi:10.5435/JAAOSGlobal-D-25-00236
  8. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Sports Med 2026.PubMed 41966639 · doi:10.1007/s40279-026-02437-0
  9. Ogórek K, Nowak K, Wadych E, et al.. Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?.Molecules 2025.PubMed 39795193 · doi:10.3390/molecules30010136
  10. Pickart L. The human tri-peptide GHK and tissue remodeling.J Biomater Sci Polym Ed 2008.PubMed 18644225 · doi:10.1163/156856208784909435
  11. Renke G, Chinellato L. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.Int J Mol Sci 2026.PubMed 42123471 · doi:10.3390/ijms27093890

Literature retrieved from PubMed on October 16, 2026, favouring human studies and reviews. Numbered markers in the text show which paper supports which statement; uncited entries are background reading.

Read this first This page compares published reference data. It is not medical advice and not a recommendation to use either compound. Several compounds documented on this site are not approved for human use.